Kane Biotech Inc.

Kane Biotech Inc. is a Canadian biotechnology company headquartered in Winnipeg, Manitoba, dedicated to the research, development, and commercialization of technologies and products designed to prevent and remove microbial biofilms. The company's core mission is to improve human and animal welfare by providing innovative solutions to challenges associated with biofilms and antimicrobial resistance.

The company's portfolio includes proprietary biotechnologies and intellectual property, with a primary focus on its revyve product line for wound care. Key products include revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser. Kane Biotech also utilizes coactiv+ and DispersinB technologies, with DispersinB having applications in both human and animal health.

In recent developments, Kane Biotech announced its Fourth Quarter and Full Year 2025 financial results on April 23, 2026. The company has been actively expanding its U.S. commercial footprint, securing non-exclusive distribution/sales agreements for its revyve Antimicrobial Wound Gel product line in February 2026. Additionally, Kane Biotech received U.S. FDA 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser in February 2026 and Health Canada approval for its revyve Antimicrobial Wound Gel Spray in December 2025. Robert Huizinga serves as the Interim CEO.